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The novel enterovirus protease inhibitor (PI) SG85 effectively inhibits the in vitro replication of 14 rhinoviruses representative
of species A and B (median 50% effective concentration, 0.04M). A low-level SG85-resistant variant was selected that carried
amino acid substitutions S127G and T143A in the 3C protease. Both substitutions are required for low-level resistance to SG85,
as demonstrated by reverse genetics. Interestingly, there is no cross-resistance to SG85 and rupintrivir (another PI); a structural
explanation is provided for this observation.
Rhinoviruses (RV) are nonenveloped, positive-sense, single-stranded RNA viruses that belong to the family of Picornaviri-
dae, genus Enterovirus (1). Currently, more than 150 RV have
been identified, which genotypically group into RV-A, RV-B, and
RV-C (2). RV infections not only cause common colds but may
also trigger exacerbations of asthma and chronic obstructive pul-
monary disease (COPD) (3–5). Because of the high (and still ris-
ing) number of variants, development of a vaccine will be hard to
achieve. Therefore, treatment with antivirals is a more realistic
strategy to reduce the burden of these infections. An RV inhibitor,
in particular, is needed for the prophylaxis and treatment of RV-
induced exacerbations of asthma and COPD (6).
The RV 3C protease (3Cpro) is a promising target for drug
development efforts because of the high level of conservation in its
substrate-binding site, its role as an indispensable enzyme for vi-
rus replication, and its unique cleavage specificity (after Gln),
which has not been observed in any other knownhost cell protease
(7–11). Peptidomimetics withMichael acceptor warheads perma-
nently disable the protease by covalent binding to its catalytic site
(12, 13). The peptidomimetic rupintrivir (Pfizer AG7088; Fig. 1)
effectively inhibits RV and enterovirus replication in vitro but
largely failed to fulfill its promise in clinical trials (14–17).
Comparison of the known crystal structures of enterovirus
3Cpros revealed that the enterovirus 68 (EV68) 3Cpro can be
considered an intermediate between the proteases of RV02 and
poliovirus (18). Therefore, it was selected for the design of broad-
spectrum enterovirus 3Cpro inhibitors, yielding SG85, a peptidic
,-unsaturated ethyl ester with Michael acceptor properties, as
the most promising candidate. SG85 is an efficient inhibitor of
EV68 3Cpro and inhibits the replication of enteroviruses in cell-
based assays (18, 19).
We demonstrate here that SG85 effectively inhibits the repli-
cation (in multicycle virus-cell-based cytopathic effect [CPE] re-
duction assays [20]) of 14 RV serotypes that are representative of
RV-A and -B (Table 1). Median 50% effective concentrations
(EC50s) of 0.04  0.02 M and 0.02  0.01 M were obtained
against RV-A and RV-B, respectively. The 3Cpro inhibitor rupin-
trivir (Axon Medchem, The Netherlands) was, on average, 4-fold
more active (Table 1), but this varied with the type (e.g., equipo-
tent activity against RV63 and 14-foldmore potent against RV02).
Akin to rupintrivir, SG85 also strongly inhibited the replication of
enterovirus 71 (EV71) and, to a lesser extent, protected cells
against coxsackievirus B3 (CVB3), echovirus 11 (ECHO11), and
poliovirus 1 (PV1) replication (18) (Table 1).
Serial passaging with increasing concentrations of SG85 for
extended periods of time did not result in the isolation of SG85-
resistant RV14 virus variants (data not shown). Instead, a clonal
selection procedure was used. To this end, several hundred in-
fected cultures (in 96-well plates) were treated with a fixed con-
centration of the compound studied equal to the EC99 or a higher
concentration. Supernatants collected from those few cultures
where a CPE developed under drug pressure were selected for
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FIG 1 Structural formulae of SG85 (A) and rupintrivir (B).
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further expansion of the virus (20). Using this method, we ob-
tained resistant variants in 1 out of 20 cultures in the case of ple-
conaril (data not shown), whereas for SG85, such variants were
observed in only 1 of 273 cultures. This suggests that the virus
quasispecies of the inoculum contained very few variants with
some natural level of resistance to the compound and/or that it is
very difficult for the virus to acquire these substitutions. The vari-
ant that was obtained proved to be4-fold less sensitive than the
wild-type virus to the antiviral effect of SG85 (data not shown).
Such a low level of drug resistance may not be clinically relevant.
However, other factors, such as the pharmacokinetic profile of the
compounds in humans, will contribute as well. Genotyping re-
vealed double mutations in the 3Cpro-encoding gene (S127G and
T143A). To confirm the causal link between the mutant genotype
and the resistant phenotype, single and double mutants were gen-
erated by using an infectious clone of RV14 (D. Blaas, Vienna,
Austria; referred to as RV14IC here). The two single mutants, i.e.,
those that carried either S127G or T143A, did not show decreased
susceptibility to the antiviral effect of SG85 (Table 2). However,
the double mutant (RV14IC S127G T143A) has low-level resis-
tance and proved 3-fold less susceptible than wild-type RV14IC to
the antiviral effect of SG85. Of note, the sensitivity of any of the
mutants to rupintrivir was not altered (Table 2). The reverse-
engineered double mutant had a level of resistance (3-fold) com-
parable to that of the phenotypically selected variant. It has been
reported that in vitro-selected rupintrivir-resistant RV14 (7- to
16-fold resistant) carries four substitutions (i.e., T129A, T131A,
Y139H, T143P) in 3C (21). Even though the quadruple mutant
also carries a substitution at position 143 (21), we did not observe
cross-resistance between SG85 (which selects for the substitutions
S127G and T143A) and rupintrivir (Table 2). In the same study,
reverse-engineered variants with a single substitution, including
one at position T143, showed no reduced susceptibility to the
antiviral effect of rupintrivir (21). This is in line with our obser-
vations that besides the substitution T143A, the substitution
S127G in 3Cpro is also required for resistance to the Michael ac-
ceptor-based peptidomimetic SG85.
SG85 and rupintrivir are less active against enterovirus species
B and C (Table 1). For a better understanding, a sequence align-
ment was made of 3Cpro of the RV strains that were used in this
study, along with the 3C sequences of an RV-C15 isolate (W1, GU
219984.1), CVB4, PV1, and EV68 (Fig. 2). The serine residue at
position 127 was conserved throughout the RV strains. At the
corresponding position (residue 128), EV68 and PV1 carry a gly-
cine, which corresponds to the substitution that was detected in
the low-level SG85-resistant RV14 variant. A crystal structure of
RV02 3Cpro in complex with a peptidic Michael acceptor (com-
pound III) revealed the presence of a hydrogen bond between the
backbone amide of the P2 residue of the inhibitor and the side
chain oxygen of S128 (22). It may be assumed that the same inter-
actionwill exist in the SG85 complex of theRV14 protease andwill
thus be lost with the S127G substitution, presumably resulting in
a loss of free energy of binding that decreases the efficiency of the
inhibitor. Rupintrivir, however, lacks a P2 backbone amide and
such a hydrogen-bonding interaction, and therefore, the S127G
substitution does not accumulate as part of a drug resistance
mechanism. It should be noted that wemademultiple attempts to
express both the wild-type and mutant proteases. However, be-
TABLE 1 Antiviral activities of SG85 and rupintrivir against 14 RV and
4 enteroviruses in virus-cell-based assays
Virus strain
Median EC50 (M)MAD
a
SG85 Rupintrivir
RV-A
RV02 0.14 0.03a 0.010 0.006a
RV09 0.032 0.008a 0.011 0.001a
RV15 0.031 0.004a 0.013 0.001a
RV29 0.04 0.03a 0.008 0.002a
RV41 0.038 0.007a 0.0036 0.0008a
RV59 0.04 0.02a 0.0102 0.0001a
RV63 0.01 0.01a 0.0106 0.0009a
RV85 0.15 0.02a 0.015 0.008a
RV89 0.05 0.06a 0.0040 0.0002a
RV-B
RV14 0.055 0.008a 0.018 0.002a
RV42 0.02 0.02a 0.0026 0.0008a
RV70 0.05 0.05a 0.0111 0.0001a
RV72 0.008 0.005a 0.00356 0.0001a
RV86 0.02 0.02a 0.0096 0.0008a
EV-A EV71 0.10 0.04a 0.004 0.002a
EV-B CVB3 0.5 0.1a 0.25 0.04a
EV-B ECHO11 33 7a 2.8 0.7a
EV-C PV1 39 18 8.2 2.7a
a Antiviral activity was determined in a CPE reduction assay with a 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
readout. The results shown are from dose-response curves set up from four or more
experiments of which at least two were independent. MAD, median absolute deviation.
b One hundred percent inhibition of a virus-induced CPE can be achieved with this
compound (as determined by microscopic inspection).
TABLE 2 Antiviral activities of SG85, rupintrivir, and pleconaril on the replication of reverse-engineered RV14IC strains that contain mutations in
the 3Cpro-encoding gene
RV14IC strain
EC50 (M)MAD (RR)
a
SG85 Rupintrivir Pleconaril
Wild type 0.018 0.001 0.010 0.001 0.327 0.004
S127G mutant 0.019 0.001 (1) 0.0094 0.0002 (1) 0.31 0.01 (1)
T143A mutant 0.018 0.001 (1) 0.008 0.001 (1) 0.108 0.004b (0.3)
S127G T143A mutant 0.047 0.001b (3) 0.012 0.001 (1) 0.13 0.02c (0.4)
a Antiviral activity was determined in a CPE reduction assay with a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium readout. Data are
in duplicate from three independent assays. The early-stage RV inhibitor pleconaril (kindly provided by V. Makarov, RAS Institute of Biochemistry, Russia) was included in this
assay as a reference. MAD, median absolute deviation. RR, relative resistance (EC50 of mutated strain/EC50 of wild type).
b P 0.0001 (unpaired t test).
c P 0.001 (unpaired t test).
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FIG 2 Alignment of the 3Cpro amino acid sequences of 15 RV (RV-A and -B) genotypes, EV68 (EV-D), and PV1 (EV-C). A yellow background indicates residues
of the catalytic triad, a purple background indicates a residue that is mutated in both the SG85- and rupintrivir-resistant RV14 variants, a blue background
indicates residues that are mutated in the SG85-resistant RV14 variant, a red background indicates residues that are mutated only in rupintrivir-resistant RV14
variants, and a green background indicates residues in the structure of the RV02 3Cpro that interact with compounds I and III (22) or residues in EV68 3Cpro that
interact with SG85 (18). This sequence alignment was created in CLC sequence viewer 7 (Qiagen).
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cause of the limited solubility of these proteins, wewere not able to
biochemically characterize these enzymes.
The threonine at position 143 is conserved in the RV-B strains,
whereas the majority of RV-A strains carry a serine (at corre-
sponding position 144) and the RV-C strain included in this anal-
ysis carries a proline. It remains to be determined whether RV-C
(3Cpro) is sensitive to SG85 (and/or rupintrivir). For RV89, EV68,
and PV1, an alanine residue is present at this position, which was
also detected in the low-level SG85-resistant RV14 variant. The
crystal structures of EV68 3Cpro in complex with SG85 (18) and of
RV 3Cpro in complex with compound III or rupintrivir (22) reveal
that whereas the main chain of residue 144 is part of the S1 pocket
of the protease, its side chain, whether Ala or Ser/Thr, is oriented
away from the inhibitor; therefore, it is not immediately clear how
the S/T143A substitution would affect the binding of the com-
pound. In agreement with these observations, both the RV14IC
S127G T143A double mutant and PV1 show decreased suscepti-
bility to the antiviral effect of SG85, whereas RV89 (which is akin
to the RV14IC singlemutant, carries only A143) is inhibited as well
as wild-type RV14IC.
Protease inhibitors (PI) are being successfully used for the
treatment of infections with HIV and hepatitis C virus. The devel-
opment of novel RV and enterovirus 3C inhibitors should be con-
sidered further. Such inhibitors have the potential to exert broad-
spectrum antiviral activity and (unlike with most HIV and HCV
PI) high-level drug-resistant variants do not, or at least do not
readily, develop. Moreover, we demonstrate here that PI of en-
terovirus and RV 3Cwith nonoverlapping drug resistance profiles
can be developed.
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